Alirocumab in Polyvascular Atherosclerotic Disease

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2020 English Publisher:Elsevier BVJournal:Journal of the American College of Cardiology, volume 75, pages 240-241 (issn: 0735-1097,

Copyright policy )

Authors: Mohammad, Alkhalil;

doi: 10.1016/j.jacc.2019.09.072

pmid: 31948655

Alirocumab in Polyvascular Atherosclerotic Disease

- Summary
- Subjects
- Metrics

Abstract

Jukema et al. ([1][1]) demonstrated in a pre-specified analysis from the ODYSSEY-OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial that alirocumab was associated with absolute risk reduction (ARR) in cardiovascular events

Keywords

Antibodies, Monoclonal, Humans, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Atherosclerosis

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average